(Fund9’s portfolio)

Remepy is pioneering Hybrid Drugs™: a new asset class combining traditional pharmaceuticals with proprietary, AI-driven treatment protocols. Within these, Remepy’s Digital Molecules™ serve as software apps tailored to specific medical conditions and medications, constantly personalized via advanced AI. By boosting neuroplasticity and balancing neuro-endocrine and neuro-immunological systems, they optimize drug performance and treat physical, motor, and psychological symptoms. Remepy partners with pharma companies to bring these combined solutions to market.